Ace Vision Group Announces Initial Close of $29.4 Million Series B Financing Round
BOSTON, April 24, 2025 (GLOBE NEWSWIRE) — Ace Vision Group, Inc, (“AVG” or “the Company”) an emerging medical device company pioneering Laser Scleral Microporation (LSM) therapy for age-related vision loss, today announced the successful close of a $29.4 million Series B financing round.
Explore More Articles
Laser scleral microporation aids near vision without compromising distance vision
LAS VEGAS — In this Healio Video Perspective from the ASCRS meeting, Robert Ang, MD, discusses results of laser scleral microporation in patients with presbyopia.
read moreVESA prediction tool could help guide presbyopia treatment
NEW ORLEANS — In this Healio Video Perspective from the ARVO meeting, AnnMarie Hipsley, DPT, PhD, founder and CEO of Ace Vision Group, speaks about the Virtual Eye Simulation Analyzer, a device with predictive diagnostic capabilities. VESA uses ray tracing technology to analyze lens changes and biomechanics related to accommodation and disaccommodation, visualizing them in virtual reality and predicting …
read moreScleral approaches to presbyopia moving from niche to mainstream
Among the many options for presbyopia, scleral approaches stand out for their unique attempt to tackle the roots of the problem, restoring physiological function rather than aiming for optical compensation. They had a slow takeoff and limited acceptance, but step by step, through a long path of research and technological upgrades, they continue to move …
read more